首页>
外国专利>
METHOD FOR DETERMINING MANAGEMENT OF PATIENTS WITH MODERATE DYSPLASTIC CHANGES IN CERVIX UTERI
METHOD FOR DETERMINING MANAGEMENT OF PATIENTS WITH MODERATE DYSPLASTIC CHANGES IN CERVIX UTERI
展开▼
机译:确定子宫中度异常增生变化的患者管理的方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to gynecology, and represents a method for determining the approach of patients with moderate dysplastic changes of the uterine cervix, consisting in the fact that performing a targeted point biopsy of the cervix uteri, immunohistochemical examination is carried out to determine expression of Ki-67 and CK7 markers, then the formula is used to calculate whether the patient belongs to the lower or upper subgroup of CIN 2:; ;group, where ƒ1(ai) = 0.266⋅X1+0.067⋅X2-12.519; ƒ2(ai) = 0.134⋅X1+0.019⋅X2-3.472; X1 is Ki-67 value; X2 is CK7 value; "0" is upper subgroup CIN 2; "1" is lower subgroup CIN 2; patients of upper CIN 2 group are predicted a progression of changes to the more severe degree CIN 3 and CIS and the cervix is excised, patients of lower CIN 2 group are predicted to regress the changes to a mild degree of CIN 1 and recommend observing for 18 months with subsequent decision on the feasibility of cervical excision.;EFFECT: method enables predicting the course of CIN 2 and determining a management approach to patients with moderate dysplastic changes in the cervix.;1 cl, 1 tbl, 2 ex;если - if;то - then
展开▼
机译:技术领域本发明涉及医学,即妇科,并且代表一种用于确定具有中等程度的子宫颈增生异常变化的患者的方法的方法,该方法包括对宫颈进行靶向性活检,进行免疫组织化学检查以确定Ki-67和CK7标志物的表达,然后使用该公式计算患者是否属于CIN 2的下部或上部亚组: ; group,其中ƒ 1 Sub>( a I> i Sub>)=0.266⋅X 1 Sub> +0.067⋅X 2 Sub> -12.519; ƒ 2 Sub>( a I> i Sub>)=0.134⋅X 1 Sub> +0.019⋅X 2 Sub > -3.472; X 1 Sub>为Ki-67值; X 2 Sub>为CK7值; “ 0”是上子组CIN 2; “ 1”是下子组CIN 2;较高CIN 2组的患者预计会发生严重程度的CIN 3和CIS改变,并切除子宫颈,较低CIN 2组的患者预计会发生CIN 1轻微程度的改变,建议观察18个月,随后就宫颈切除的可行性做出决定。;效果:该方法能够预测CIN 2的病程并确定对子宫颈中度异常增生性改变的患者的治疗方法。1cl,1 tbl,2 ex;если-如果;то-然后
展开▼